Table II.
List of publications concerning esophageal cancer outcomes in the elderly and the most important data about the population
| Authors | Histology, n (%) | Tumor stage, n (%) | Tumor site | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SCC | AC | Other | 0 | I | II | III | IV | L1/3 | M1/3 | U1/3 | |
| Cummings et al. (OE group) | 261 (29.23) | 632 (70.77) | 0 (0) | 88 (9.9) | 805 (90.1) | 0 (0) | 0 (0) | 0 (0) | nd | nd | nd |
| Liu, Huang et al. (≥ 70 y group) | 30 (76.9) | 9 (23.1) | 0 (0) | 0 (0) | 0 (0) | 20 (51.3) | 14 (35.9) | 5 (12.8) | 17 (43.6) | 16 (41.0) | 6 (15.4) |
| Li et al. (OE group) | 58 (100) | 0 (0) | 0 (0) | 0 (0) | 3 (5.2) | 30 (51.7) | 25 (43.1) | 0 (0) | 6 (10.3) | 42 (72.4) | 10 (17.2) |
| Aydin et al. | 27 (73.0) | 6 (16.2) | 4 (10.8) | 0 (0) | 4 (10.8) | 19 (51.4) | 14 (37.8) | 0 (0) | 18 (48.6) | 17 (46.0) | 2 (5.4) |
| Pultrum et al. (≥ 70 y group) | 8 (13) | 56 (87) | 0 (0) | 0 (0) | 11 (17) | 25 (52) | 25 (39) | 3 (5) | 60 (94) | 4 (6) | 0 (0) |
| Liu, Chen et al. (≥ 70 y group) | 26 (89.7) | 3 (10.3) | 0 (0) | 0 (0) | 0 (0) | 14 (48.2) | 11 (37.9) | 4 (13.8) | 13 (44.8) | 11 (37.9) | 5 (17.2) |
| Kosugi et al. (OE group) | 40 (100) | 0 (0) | 0 (0) | 0 (0) | 11 (27.5) | 15 (37.5) | 11 (27.5) | 3 (7.5) | 18 (45.0) | 19 (47.5) | 3 (7.5) |
| Abrams et al. (OE group) | 94 (27.5) | 213 (62.5) | 34 (10.0) | 0 (0) | 177 (51.9) | 164 (48.1) | 0 (0) | 0 (0) | nd | nd | nd |
| Internullo et al. | 26 (24) | 80 (74) | 2 (1.8) | 6 (5.5) | 29 (26.8) | 25 (23.1) | 29 (26.7) | 19 (17.5) | 93 (86.1) | 13 (12) | 2 (1.8) |
| Ruol et al. (≥ 70 y group) | 77 (48.4) | 77 (48.4) | 5 (3.2) | 5 (3.2) | 20 (12.7) | 71 (44.2) | 50 (31.9) | 11 (7.0) | 94 (59.1) | 37 (23.3) | 28 (17.6) |
| Ma et al. (≥ 70 y group) | 53 (88.3) | 4 (6.7) | 3 (5.0) | 1 (1.7) | 2 (2.2) | 9 (15.0) | 45 (75.0) | 3 (5.0) | 16 (26.7) | 32 (53.3) | 10 (16.7) |
| Mirza et al. (≥ 70 y group) | 45 (97.83) | 1 (2.17) | 0 (0) | nd | nd | nd | nd | nd | nd | nd | nd |
| Li et al. (MIE group) | 58 (100) | 0 (0) | 0 (0) | 0 (0) | 4 (6.9) | 31 (53.4) | 23 (39.7) | 0 (0) | 8 (13.8) | 44 (75.9) | 6 (10.3) |
| Cummings et al. (ET group) | 78 (31) | 177 (69) | 0 | 60 (23.5) | 195 (76.5) | 0 (0) | 0 (0) | 0 (0) | nd | nd | nd |
| Kikuchi et al. (≥ 75 y group) | 13 (100) | 0 (0) | 0 (0) | nd | nd | nd | nd | nd | 1 (8) | 9 (69) | 3 (23) |
| Wakui et al. | 22 (100) | nd | nd | 0 (0) | 3 (13.64) | 6 (27.27) | 12 (54.55) | 1 (4.55) | nd | 10 (46) | nd |
| Kosugi et al. (CRT group) | 24 (100) | 0 (0) | 0 (0) | 0 (0) | 1 (4.2) | 14 (58.3) | 7 (29.2) | 2 (8.4) | 3 (12.5) | 15 (62.5) | 6 (25.0) |
| Abrams et al. (CRT group) | 209 (53.7) | 141 (36.3) | 39 (10.0) | 0 (0) | 232 (59.6) | 157 (40.4) | 0 (0) | 0 (0) | nd | nd | nd |
| Tougeron, Di Fiore et al. | 77 (70.6) | 28 (25.7) | 4 (3.7) | 0 (0) | 2 (1.8) | 50 (45.9) | 46 (42.2) | 6 (5.5) | 52 (47.7) | 36 (33.3) | 21 (19.3) |
| Anderson et al. | 13 (52) | 12 (48) | 0 (0) | 0 (0) | 0 (0) | 8 (32) | 17 (68) | 0 (0) | nd | nd | nd |
| Tougeron et al. (curative treatment) | 103 (70.1) | 44 (29.9) | 0 (0) | 0 (0) | 24 (15.9) | 61 (40.4) | 51 (33.8) | 7 (4.6) | 80 (60.0) | 44 (29.1) | 27 (17.9) |
| Tougeron et al. (palliative treatment group) | 17 (56.7) | 12 (40.0) | 1 (3.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 30 (100) | 19 (63.3) | 9 (30.0) | 2 (6.7) |
| Tougeron et al. (BSC group) | 63 (67.02) | 27 (28.72) | 4 (4.26) | 0 (0) | 3 (4.3) | 7 (10.1) | 18 (26.1) | 1 (1.4) | 52 (51.49) | 33 (32.67) | 16 (15.84) |
| Tapias et al. (70–79 y group) | 15 (12.1) | 100 (80.7) | 9 (7.2) | 7 (6.2) | 34 (30.1) | 29 (25.7) | 43 (38.1) | 0 (0) | nd | nd | nd |
| Tapias et al. (≥ 80 y group) | 2 (12.5) | 14 (87.5) | 0 (0) | 0 (0) | 5 (35.7) | 5 (35.7) | 4 (28.6) | 0 (0) | nd | nd | nd |
| Steyerberg et al. | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
L1/3 – lower third, M1/3 – middle third, U1/3 – upper third, SCC – squamous cell carcinoma, AC – adenocarcinoma, nd – no data.